Tandem Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Tandem Diabetes Care
TNDM Stock  USD 19.89  0.13  0.66%   
Tandem Diabetes' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Tandem Diabetes' valuation are provided below:
Gross Profit
536 M
Profit Margin
(0.20)
Market Capitalization
1.3 B
Enterprise Value Revenue
1.4692
Revenue
1 B
There are over one hundred nineteen available fundamental trend indicators for Tandem Diabetes Care, which can be analyzed over time and compared to other ratios. Self-guided Investors are advised to double-check Tandem Diabetes' current fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 1st of February 2026, Market Cap is likely to grow to about 1.8 B. Also, Enterprise Value is likely to grow to about 2.2 B

Tandem Diabetes Total Revenue

1.14 Billion

Check Tandem Diabetes financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tandem Diabetes' main balance sheet or income statement drivers, such as Depreciation And Amortization of 172.6 K, Interest Expense of 6.4 M or Selling General Administrative of 470.7 M, as well as many indicators such as Price To Sales Ratio of 2.74, Dividend Yield of 0.0 or PTB Ratio of 5.14. Tandem financial statements analysis is a perfect complement when working with Tandem Diabetes Valuation or Volatility modules.
  
Build AI portfolio with Tandem Stock
Check out the analysis of Tandem Diabetes Correlation against competitors.

Tandem Diabetes Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1.2 B1.1 B475.2 M
Slightly volatile
Short and Long Term Debt Total571.8 M544.6 M194.9 M
Slightly volatile
Other Current Liabilities158.9 M151.4 M55 M
Slightly volatile
Total Current Liabilities298.3 M284.1 M104 M
Slightly volatile
Other Liabilities43.6 M41.5 M18.8 M
Slightly volatile
Property Plant And Equipment Net197.4 M188 M70.5 M
Slightly volatile
Accounts Payable54 M51.4 M24.2 M
Slightly volatile
Cash66.2 M79.6 M58.6 M
Slightly volatile
Non Current Assets Total293.6 M279.6 M93.2 M
Slightly volatile
Non Currrent Assets Other7.1 M4.9 M5.6 M
Slightly volatile
Cash And Short Term Investments259.2 M504.1 M239.5 M
Slightly volatile
Net Receivables138.4 M131.8 M55.4 M
Slightly volatile
Common Stock Total Equity71 K74.8 K876.5 K
Pretty Stable
Common Stock Shares Outstanding79 M75.3 M35.1 M
Slightly volatile
Short Term Investments445.7 M424.5 M195.7 M
Slightly volatile
Liabilities And Stockholders Equity1.2 B1.1 B475.2 M
Slightly volatile
Non Current Liabilities Total552.4 M526.1 M211.6 M
Slightly volatile
Inventory180.7 M172.1 M62.8 M
Slightly volatile
Other Current Assets26.5 M25.3 M8.4 M
Slightly volatile
Other Stockholder Equity1.6 B1.5 B724.8 M
Slightly volatile
Total Liabilities850.8 M810.2 M315.6 M
Slightly volatile
Property Plant And Equipment Gross273.2 M260.2 M84.9 M
Slightly volatile
Total Current Assets874.8 M833.2 M382 M
Slightly volatile
Short Term Debt71.1 M67.7 M30.1 M
Slightly volatile
Common Stock43.8 K75.9 K39.8 K
Slightly volatile
Property Plant Equipment82.8 M78.8 M35.9 M
Slightly volatile
Current Deferred Revenue9.5 M13.6 M8.2 M
Slightly volatile
Intangible Assets1 M1.1 M2.8 M
Very volatile
Long Term Debt372.2 M354.5 M166.2 M
Slightly volatile
Long Term Debt Total339.9 M323.7 M160.6 M
Slightly volatile
Capital Surpluse776.1 M1.3 B707.5 M
Slightly volatile
Deferred Long Term Liabilities3.6 M4.4 M3.4 M
Slightly volatile
Short and Long Term Debt56.1 M46.8 M42.3 M
Slightly volatile
Non Current Liabilities Other24.4 M37.2 M18.3 M
Slightly volatile
Net Invested Capital493.8 M703.8 M301.2 M
Slightly volatile
Net Working Capital447.5 M549.1 M261.6 M
Slightly volatile
Capital Stock69 K75.9 K61.2 K
Slightly volatile
Capital Lease Obligations86.3 M143.3 M52 M
Slightly volatile

Tandem Diabetes Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization172.6 K181.7 K5.7 M
Slightly volatile
Interest Expense6.4 M8.5 M5.7 M
Slightly volatile
Selling General Administrative470.7 M448.3 M186.5 M
Slightly volatile
Other Operating Expenses1.3 B1.2 B466 M
Slightly volatile
Research Development240.1 M228.7 M83.8 M
Slightly volatile
Total Operating Expenses710.9 M677 M269.5 M
Slightly volatile
Selling And Marketing Expenses898.7 K1.1 M850.2 K
Slightly volatile
Total Revenue1.1 B1.1 B400.3 M
Slightly volatile
Cost Of Revenue544.1 M518.2 M196.9 M
Slightly volatile
Interest Income21.7 M20.7 M6.9 M
Slightly volatile
Reconciled Depreciation12.3 M19.1 M10 M
Slightly volatile
Extraordinary Items41.3 M46.4 M50.7 M
Slightly volatile
Non Recurring24.8 M27.9 M30.5 M
Slightly volatile

Tandem Diabetes Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation122.4 M116.6 M45.4 M
Slightly volatile
Begin Period Cash Flow62.4 M67.7 M55 M
Slightly volatile
Depreciation20.1 M19.1 M8.9 M
Slightly volatile
Other Non Cash Items23.8 M16.1 M20.2 M
Slightly volatile
Capital Expenditures15.4 M22.1 M13.8 M
Slightly volatile
Total Cash From Financing Activities7.2 M7.5 M55.8 M
Very volatile
End Period Cash Flow66.2 M79.6 M58.6 M
Slightly volatile
Change To Netincome147 M140 M63.9 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.742.8822.5767
Slightly volatile
Days Sales Outstanding89.2151.16113
Slightly volatile
Stock Based Compensation To Revenue0.150.120.1343
Pretty Stable
Capex To Depreciation1.381.041.6225
Very volatile
EV To Sales3.213.3821.6517
Slightly volatile
Inventory Turnover2.412.712.6751
Slightly volatile
Days Of Inventory On Hand173139209
Slightly volatile
Payables Turnover8.129.079.0354
Slightly volatile
Sales General And Administrative To Revenue0.880.922.3934
Slightly volatile
Research And Ddevelopement To Revenue0.230.240.8257
Slightly volatile
Capex To Revenue0.02230.02350.4444
Slightly volatile
Cash Per Share7.327.712.9151
Slightly volatile
Days Payables Outstanding50.4141.6659.4812
Slightly volatile
Intangibles To Total Assets0.0010.00110.0207
Slightly volatile
Current Ratio3.22.643.6714
Pretty Stable
Receivables Turnover4.837.385.4599
Slightly volatile
Capex Per Share0.320.341.191
Slightly volatile
Average Receivables1.1 M1.2 M1.3 M
Slightly volatile
Revenue Per Share14.8416.5212.3954
Pretty Stable
Interest Debt Per Share10.228.459.3782
Slightly volatile
Debt To Assets0.450.560.4277
Pretty Stable
Graham Number4.945.566.0725
Slightly volatile
Operating Cycle262191322
Slightly volatile
Days Of Payables Outstanding50.4141.6659.4812
Slightly volatile
Ebt Per Ebit1.140.831.3549
Very volatile
Long Term Debt To Capitalization0.460.490.4704
Pretty Stable
Quick Ratio2.752.093.1516
Very volatile
Net Income Per E B T0.80.940.9854
Slightly volatile
Cash Ratio0.310.321.2097
Slightly volatile
Cash Conversion Cycle212149262
Slightly volatile
Days Of Inventory Outstanding173139209
Slightly volatile
Days Of Sales Outstanding89.2151.16113
Slightly volatile
Fixed Asset Turnover4.385.184.7741
Slightly volatile
Debt Ratio0.450.560.4277
Pretty Stable
Price Sales Ratio2.742.8822.5767
Slightly volatile
Asset Turnover0.560.870.6303
Slightly volatile

Tandem Diabetes Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.8 B1.7 B1.5 B
Slightly volatile
Enterprise Value2.2 B2 B1.8 B
Slightly volatile

Tandem Fundamental Market Drivers

Forward Price Earnings1111.1111
Cash And Short Term Investments438.3 M

Tandem Upcoming Events

21st of February 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
21st of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Tandem Diabetes Financial Statements

Tandem Diabetes investors utilize fundamental indicators, such as revenue or net income, to predict how Tandem Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue13.6 M9.5 M
Total Revenue1.1 B1.1 B
Cost Of Revenue518.2 M544.1 M
Stock Based Compensation To Revenue 0.12  0.15 
Sales General And Administrative To Revenue 0.92  0.88 
Research And Ddevelopement To Revenue 0.24  0.23 
Capex To Revenue 0.02  0.02 
Revenue Per Share 16.52  14.84 
Ebit Per Revenue(0.09)(0.10)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Tandem Diabetes Care is a strong investment it is important to analyze Tandem Diabetes' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Tandem Diabetes' future performance. For an informed investment choice regarding Tandem Stock, refer to the following important reports:
How To Invest In Tandem
Details
Is Tandem Stock a good investment?
Details
What is Tandem Diabetes' Net Worth?
Details
Largest Health Care Equipment & Supplies Companies
View
Largest Health Care Equipment & Services Companies
View
Check out the analysis of Tandem Diabetes Correlation against competitors.
You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Will Health Care Equipment & Supplies sector continue expanding? Could Tandem diversify its offerings? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Tandem Diabetes data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth
(0.37)
Earnings Share
(3.03)
Revenue Per Share
15.083
Quarterly Revenue Growth
0.022
Return On Assets
(0.06)
Understanding Tandem Diabetes Care requires distinguishing between market price and book value, where the latter reflects Tandem's accounting equity. The concept of intrinsic value—what Tandem Diabetes' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Tandem Diabetes' price substantially above or below its fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Tandem Diabetes' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY